You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handout How to Safely Take Your Oral Anti-Cancer Medication.

Displaying Drugs List

46 Items
Other Name(s): Zytiga® (Janssen)
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
Sep 2019
Other Name(s): Giotrif®
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Jun 2019
Other Name(s): Alecensaro™
Funding:
Exceptional Access Program
  • Treatment of non-small cell lung cancer according to clinical criteria
Jun 2019
Other Name(s): Erleada®
Funding:
Exceptional Access Program
  • apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Updated
Jan 2020
Other Name(s): Inlyta®
Funding:
Exceptional Access Program
  • aXitinib - For the treatment of metastatic renal cell carcinoma of clear cell histology (second-line), according to clinical criteria
Jun 2019
Other Name(s): Bosulif®
Funding:
Exceptional Access Program
  • bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Jun 2019
Other Name(s): Zykadia™
Funding:
Exceptional Access Program
  • ceritinib - Second-line monotherapy of ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC, in patients who have experienced disease progression or intolerance to crizotinib, according to specific criteria
Aug 2019
Other Name(s): Cotellic™
Funding:
Exceptional Access Program
  • cobimetinib - For combination therapy (with vemurafenib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage III or IV melanoma
Jun 2019
Other Name(s): Xalkori® (Pfizer)
Funding:
Exceptional Access Program
  • crizotinib - ALK-positive advanced NSCLC, according to specific criteria
Sep 2017
Other Name(s): Tafinlar®
Funding:
Exceptional Access Program
  • daBRAfenib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
  • daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
  • daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Updated
Jan 2020
Other Name(s): Aranesp ® (Amgen)
Funding:
Exceptional Access Program
  • darbepoetin - Anemia secondary to MDS, with specific criteria
ODB Limited Use
  • darbepoetin - Patients with cancer diagnosis and receiving chemotherapy, with specific criteria
Aug 2018
Other Name(s): Sprycel®
Funding:
Exceptional Access Program
  • daSAtinib - PH+ ALL, with specific criteria
  • daSAtinib - Ph+ CML in the chronic phase, with specific criteria
  • daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Jun 2019